Featured
Read our handpicked blogs, curated for you.
|
The Enforcement Horizon: August 2, 2026The industry consensus is dominated by the EU AI Act. As of mid-2026, AI systems…
|
The 2026 Industry Consensus: From Policies to EnforcementThe prevailing consensus among global Tier-1 banks is the…
|
The 2026 Industry Consensus: Unified Systems OrchestrationThe prevailing consensus in 2026 is that "more models…
Recent releases
|
Content Velocity in Pharma: Why Speed is the New Compliance
Content Velocity in Pharma has quietly become the metric that separates companies who talk about digital transformation from those who execute it. Indian pharma firms are spending heavily on…
|
What Every CMO Wants From Their Pharma Tech Stack in 2025
Five years ago, tech stack conversations in pharma happened in IT departments. Today, they sit squarely on the CMO’s desk. Marketing leaders no longer care about tools in isolation, they care about…
|
Tier 2 and Tier 3 Doctors The Untapped Goldmine of Indian Pharma Marketing
For decades, Indian pharma marketing has revolved around Tier 1 cities. Mumbai, Delhi, Bangalore, Chennai- this is where companies concentrated their field force, budgets, and campaigns. But here’s…
|
Tier 2 and Tier 3 Doctors: Pharma’s Untapped Growth Engine
For years, Indian pharma marketing has been obsessed with metros. Strategies are designed for doctors in Mumbai, Delhi, Bangalore, and Hyderabad, as if prescribing behavior outside these hubs hardly…
